1<!DOCTYPE html>
2
3Anonymous
4/bestp
5/bestp/domrep.nsf
6C77D45ECD2B57C75002585460023B341
8
9
10
11
12
13
140
15
16
17/bestp/domrep.nsf/products/changes-outreach-communications-stakeholders-during-global-covid-19-pandemic
18
19
203.236.159.130
21
22
23www.best-in-class.com
24/bestp/domrep.nsf
25BMR




» Products & Services » » Business Communications » External Communication Excellence

Changes in Outreach and Communications with Stakeholders during the Global COVID-19 Pandemic

ID: CM-1


Features:

5 Info Graphics

12 Data Graphics

140+ Metrics


Pages: 29


Published: 2020


Delivery Format: Shipped


 

License Options:
close

Single User: Authorizes use by the person who places the order or for whom the order was placed.

Sitewide: Authorizes use of the report for a geographic site. All people at site can view the report for a year and copies can be printed.

Corporate: Authorizes use for the entire company for a year and copies can be printed. No limitations for usage inside the company.




Buy Now

 

919-403-0251

  • STUDY OVERVIEW
  • BENCHMARK CLASS
  • STUDY SNAPSHOT
  • KEY FINDINGS
  • VIEW TOC AND LIST OF EXHIBITS
With the COVID-19 outbreak impacting key business operations across the world, organizations have had to adapt their outreach and communication policies to continue their support to patients and interact with physicians, thought leaders and other stakeholders during this critical hour. Indeed, many companies have moved quickly to provide virtual tools to mitigate work disruptions based on the strict limitations on face-to-face engagements.


Best Practices, LLC conducted this benchmarking research to find out how companies are addressing their limited access to external stakeholders during the COVID-19 pandemic.

This report uncovers the external engagement approaches and operational tactics that life sciences companies have implemented in the immediate aftermath of the COVID-19 pandemic outbreak. It examines the creation of global COVID-19 pandemic task forces, external engagement policies, necessary resources, and new metrics used to measure performance during this pandemic.


Industries Profiled:
Pharmaceutical; Biotech; Manufacturing; Biopharmaceutical; Consulting; Medical Device; Health Care; Consumer Products; Communications; Clinical Research; Laboratories


Companies Profiled:
Advanced Accelerator Applications; Allergan; Almirall; Amgen; Amicus Therapeutics; Biogen; Boehringer Ingelheim; Cara Therapeutics; Cascadia Drug Development Group; Cipla; FerGene; Getz Pharma; Greenwich Biosciences; Grünenthal; Ipsen; Kaleo; Kiniksa Pharmaceuticals; LEO Pharma; Medicure; Medtronic; Melinta Therapeutics; Inc; Merck; Nestle; NexGen Healthcare Communications; Novartis; Novo Nordisk; Osmotica Pharmaceuticals; Roche; Sanofi; Servier; Surrozen; Takeda Pharmaceuticals; Tecan; TG Therapeutics; Zeiss Pharma

Study Snapshot

Best Practices, LLC engaged 36 leaders from 35 leading biopharma companies in this research. Seventy-two percent of the research participants serve at the director/ senior director level.

Key topics covered in this report include:

  • Implementation of global COVID-19 pandemic task force
  • External engagement policies and limitations
  • Digital external engagements
  • Challenges and issues prevalent due to the global COVID-19 pandemic
  • Requisite resources
  • Response to constraints in travel and visitation
  • Performance tracking during the pandemic

Key Findings

Select key insights uncovered from this report are noted below. Detailed findings are available in the full report.

  • F2F interactions with physicians are generally transferable to a digital video alternative:

    • 42% of companies do not currently allow face-to-face external engagements with physicians.
    • 42% of companies have implemented digital remote engagement alternatives to F2F engagements with physicians, indicating these engagements are essentially fully transferable to digital.

  • 2 out of 3 are changing their KPIs and/or other performance measures:

    • 66% of companies are changing their performance measures to reflect the challenge of transferring external engagements to digital or other means.
Table of Contents

Sr. No.
Topic
Slide No.
I.
Overviewpgs. 3-6
Universe of Learningpg. 4
Key Actionspg. 5
II.
Task Forcepgs. 7-9
III.
External Engagementspgs. 10-13
IV.
Digital External Engagementspgs. 14-16
V.
Challenges and Issuespgs. 17-19
VI.
Necessary Resourcespgs. 20-21
VII.
Response to Constraints in Travel and Visitationpgs. 22-23
VIII.
Performance Metricspgs. 24-25
IX.
Participant Demographicspgs. 26-28
X.
About Best Practices, LLCpg. 29